Pharmalot... Pharmalittle... Good Morning

Good morning, everyone, and welcome to the working week. We had a longer-than-usual weekend break and must now play catch up as a result. This is a familiar phenomenon, yes? The world never stops spinning even when we hit the pause button. And so, we are fortifying ourselves with that ever-familiar cup of stimulation and invite you to join us. And why not? If the temperature where you are is anything like the chilly Pharmalot corporate campus, what have you got to lose? While you ponder, here are some tidbits. Have a great day and do stay in touch... Orexigen Weight-Loss Pill Passes Safety Hurdle (TheStreet) Biogen Wins Added EU Protection For Tecfidera MS Drug (Bloomberg News) Ranbaxy May Sell Biovel Vaccine Unit (The Business Standard) FDA Says DTC Genetic Testing Kit Is Misbranded (Regulatory Focus) Novartis Starts $5 Billion Buyback And Eyes Asset Sales (Reuters) Swiss Voters Reject Strict CEO Pay Limits In Referendum (Bloomberg News) EU Allows Ariad Cancer Drug To Remain, But With Restrictions (PM Live) ...Read more
Source: Pharmalot - Category: Pharma Commentators Authors: Source Type: blogs